We are live on ! Find out more
MIM

Monashee Investment Management Portfolio holdings

AUM $184M
1-Year Est. Return 197.43%
This Fund
S&P 500
This Quarter Est. Return
+5.59%
1 Year Est. Return
+197.43%
3 Year Est. Return
+447.04%
5 Year Est. Return
+479.31%
10 Year Est. Return
+5,610.42%
AUM
$270M
AUM Growth
-$5.09M
Cap. Flow
+$1.98M
Cap. Flow %
0.73%
Top 10 Hldgs %
77.59%
Holding
68
New
41
Increased
2
Reduced
6
Closed
16

Top Buys

Rank Stock Value
1
QQQ icon
Invesco QQQ Trust
QQQ
+$98.7M
2
GOSS icon
Gossamer Bio
GOSS
+$8.61M
3
PM icon
Philip Morris
PM
+$6.2M
4
CRBG icon
Corebridge Financial
CRBG
+$5.14M
5
ARGX icon
argenx
ARGX
+$4.45M

Sector Composition

Rank Sector Weight
1 Healthcare 18.97%
2 Financials 2.55%
3 Consumer Staples 2%
4 Materials 1.3%
5 Energy 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACDC icon
26
ProFrac Holding
ACDC
$787M
$1.45M 0.54%
95,000
+65,000
+217% +$1.17M
FRC
27
DELISTED
First Republic Bank
FRC
$1.31M 0.48%
+10,000
New +$1.54M
AMPS
28
DELISTED
Altus Power
AMPS
$1.2M 0.44%
+108,700
New +$1.04M
PYCR
29
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
$1.03M 0.38%
+35,000
New +$1.01M
TSVT
30
DELISTED
2seventy bio
TSVT
$1.02M 0.38%
70,000
-10,000
-13% -$148K
CINC
31
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$985K 0.37%
+30,000
New +$848K
IDYA icon
32
IDEAYA Biosciences
IDYA
$3.56B
$895K 0.33%
+60,000
New +$779K
THRD
33
DELISTED
Third Harmonic Bio
THRD
$759K 0.28%
+40,000
New +$721K
ALPN
34
DELISTED
Alpine Immune Sciences Inc
ALPN
$720K 0.27%
+100,000
New +$824K
RLAY icon
35
Relay Therapeutics
RLAY
$4.33B
$680K 0.25%
+30,400
New +$667K
MIRM icon
36
Mirum Pharmaceuticals
MIRM
$6.14B
$630K 0.23%
+30,000
New +$722K
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$29.3B
$600K 0.22%
+3,000
New +$572K
SMRT icon
38
SmartRent
SMRT
$272M
$454K 0.17%
+200,000
New +$789K
LXU icon
39
LSB Industries
LXU
$693M
$449K 0.17%
+31,500
New +$446K
PAX icon
40
Patria Investments
PAX
$1.86B
$392K 0.15%
+30,000
New +$419K
BLU
41
DELISTED
BELLUS Health Inc.
BLU
$317K 0.12%
+30,000
New +$319K
CDTX
42
DELISTED
Cidara Therapeutics
CDTX
$232K 0.09%
+18,455
New +$255K
KNBE
43
DELISTED
KnowBe4, Inc. Class A Common Stock
KNBE
$208K 0.08%
+10,000
New +$184K
SRZNW icon
44
Surrozen Inc Warrant
SRZNW
$8.86K
$23K 0.01%
127,280
ACI icon
45
Albertsons Companies
ACI
$5.83B
-125,000
Closed -$3.34M
ACLX
46
DELISTED
Arcellx
ACLX
-122,129
Closed -$2.21M
AMT icon
47
American Tower
AMT
$80.4B
-15,000
Closed -$3.83M
ASPN icon
48
Aspen Aerogels
ASPN
$518M
-37,500
Closed -$371K
CRNX icon
49
Crinetics Pharmaceuticals
CRNX
$8.92B
-95,000
Closed -$1.77M
CYTK icon
50
Cytokinetics
CYTK
$10.4B
-45,000
Closed -$1.77M

Similar funds

Monashee Investment Management's Q3 2022 Portfolio in Review

As of Q3 2022, Monashee Investment Management held 68 positions worth $270M, down 1.9% from $275M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Monashee Investment Management's Q3 2022 filing shows 41 new, 2 increased, 6 reduced and 16 closed positions. Its largest new stake was Invesco QQQ Trust: 327,000 shares worth $87.4M. The largest sale was Vanguard Morningstar Total Stock Market ETF, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 12% a quarter earlier, followed by Financials and Consumer Staples.

  • Monashee Investment Management's largest Q3 2022 buy was Invesco QQQ Trust: 327,000 shares worth $87.4M.
  • Monashee Investment Management added most to ProFrac Holding in Q3 2022, an estimated $1.17M increase.
  • Monashee Investment Management's biggest Q3 2022 reduction was Vanguard Morningstar Total Stock Market ETF, cutting an estimated $144M.
  • Monashee Investment Management fully exited Hyperfine in Q3 2022, selling an estimated $3.89M.
  • Monashee Investment Management's ten largest holdings make up 78% of its $270M portfolio in Q3 2022.
  • Monashee Investment Management opened 41 new positions and closed 16 in Q3 2022.
  • Monashee Investment Management's portfolio value fell 1.9% quarter-over-quarter to $270M.

Based on Monashee Investment Management's 13F filing for Q3 2022, filed 1 Nov 2022.